7-Bromo-4H-pyrido[1,2-a]pyrimidine-4-oxo-3-carboxylic acid
![]() |
- $203 - $1882
- Product name: 7-Bromo-4H-pyrido[1,2-a]pyrimidine-4-oxo-3-carboxylic acid
- CAS: 953754-98-8
- MF: C9H5BrN2O3
- MW: 269.05
- EINECS:
- MDL Number:MFCD09730702
- Synonyms:7-Bromo-4H-pyrido[1,2-a]pyrimidine-4-oxo-3-carboxylic acid;7-bromo-4-oxopyrido[1,2-a]pyrimidine-3-carboxylic acid;4H-Pyrido[1,2-a]pyrimidine-3-carboxylic acid, 7-bromo-4-oxo-
3 prices
Selected condition:
Brand
- AK Scientific
- Crysdot
- Matrix Scientific
Package
- 100mg
- 1g
- ManufacturerAK Scientific
- Product number1698CX
- Product description7-Bromo-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxylicacid
- Packaging100mg
- Price$203
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD11004409
- Product description7-Bromo-4-oxo-4H-pyrido[1,2-a]-pyrimidine-3-carboxylicacid 95+%
- Packaging1g
- Price$1127
- Updated2021-12-16
- Buy
- ManufacturerMatrix Scientific
- Product number123411
- Product description7-Bromo-4-oxo-4H-pyrido[1,2-a]-pyrimidine-3-carboxylicacid 95+%
- Packaging1g
- Price$1882
- Updated2021-12-16
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
AK Scientific | 1698CX | 7-Bromo-4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxylicacid | 100mg | $203 | 2021-12-16 | Buy |
Crysdot | CD11004409 | 7-Bromo-4-oxo-4H-pyrido[1,2-a]-pyrimidine-3-carboxylicacid 95+% | 1g | $1127 | 2021-12-16 | Buy |
Matrix Scientific | 123411 | 7-Bromo-4-oxo-4H-pyrido[1,2-a]-pyrimidine-3-carboxylicacid 95+% | 1g | $1882 | 2021-12-16 | Buy |
Properties
Boiling point :370.1±52.0 °C(Predicted)
Density :1.91±0.1 g/cm3(Predicted)
pka :-0.82±0.40(Predicted)
Density :1.91±0.1 g/cm3(Predicted)
pka :-0.82±0.40(Predicted)
Safety Information
Symbol(GHS): |
![]() |
|||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal word: | Warning | |||||||||||||||||||||||||||||||||||
Hazard statements: |
|
|||||||||||||||||||||||||||||||||||
Precautionary statements: |
|